|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-3-26
|
|
pubmed:abstractText |
Survival of patients with primary central nervous system lymphoma (PCNSL) has improved with methotrexate-based combination regimens and radiotherapy (RT). However, the prognosis of patients who fail or relapse after initial response is poor. Very little data is available on salvage treatment at recurrence.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0902-4441
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
219-24
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12656744-Adolescent,
pubmed-meshheading:12656744-Adult,
pubmed-meshheading:12656744-Aged,
pubmed-meshheading:12656744-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12656744-Brain Neoplasms,
pubmed-meshheading:12656744-Carmustine,
pubmed-meshheading:12656744-Child, Preschool,
pubmed-meshheading:12656744-Clinical Trials, Phase II as Topic,
pubmed-meshheading:12656744-Combined Modality Therapy,
pubmed-meshheading:12656744-Cranial Irradiation,
pubmed-meshheading:12656744-Cyclophosphamide,
pubmed-meshheading:12656744-Cytarabine,
pubmed-meshheading:12656744-Dexamethasone,
pubmed-meshheading:12656744-Disease-Free Survival,
pubmed-meshheading:12656744-Doxorubicin,
pubmed-meshheading:12656744-Drug Evaluation,
pubmed-meshheading:12656744-Etoposide,
pubmed-meshheading:12656744-Female,
pubmed-meshheading:12656744-Humans,
pubmed-meshheading:12656744-Ifosfamide,
pubmed-meshheading:12656744-Life Tables,
pubmed-meshheading:12656744-Lymphoma, Non-Hodgkin,
pubmed-meshheading:12656744-Male,
pubmed-meshheading:12656744-Methotrexate,
pubmed-meshheading:12656744-Middle Aged,
pubmed-meshheading:12656744-Neoplasm Recurrence, Local,
pubmed-meshheading:12656744-Neutropenia,
pubmed-meshheading:12656744-Remission Induction,
pubmed-meshheading:12656744-Retrospective Studies,
pubmed-meshheading:12656744-Salvage Therapy,
pubmed-meshheading:12656744-Survival Analysis,
pubmed-meshheading:12656744-Thrombocytopenia,
pubmed-meshheading:12656744-Vincristine
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
|
|
pubmed:affiliation |
Service of Hematology, Institut de Recerca Biomèdica August Pi i Sunyer, Hospital Clínic, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article
|
